Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle

被引：0
|
作者：
Brin, Mitchell F. [1 ,2 ]
Winner, Paul [3 ]
Blumenfeld, Andrew M. [4 ]
Eross, Eric J. [5 ]
Orejudos, Amelia [1 ]
Adams, Aubrey Manack [1 ]
机构：
[1] Allergan Plc, Irvine, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
[3] Premiere Res Inst Palm Beach Neurol, Palm Beach Headache Ctr, W Palm Beach, FL USA
[4] Headache Ctr Southern Calif, Neurol Ctr, Carslbad, CA USA
[5] CORE Inst, Scottsdale, AZ USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P4.123
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Winner, P. K.
    Blumenfeld, A.
    Eross, E. J.
    Orejudos, A.
    Adams, Manack A.
    Brin, M. F.
    HEADACHE, 2018, 58 : 105 - 105
  • [2] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Brin, Mitchell F.
    CEPHALALGIA, 2017, 37 : 93 - +
  • [3] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia C.
    Mirjah, Debbie L.
    Adams, Aubrey Manack
    Brin, Mitchell F.
    DRUG SAFETY, 2019, 42 (08) : 1013 - 1024
  • [4] LONG-TERM SAFETY AND TOLERABILITY OF ONABOTULINUMTOXINA TREATMENT IN CHRONIC MIGRAINE PATIENTS TAKING ORAL PREVENTIVE MEDICATIONS: COMPEL ANALYSIS BY TREATMENT CYCLE
    Winner, P. K.
    Blumenfeld, A. M.
    Eross, E. J.
    Orejudos, A.
    Adams, A. Manack
    Brin, M. F.
    CEPHALALGIA, 2018, 38 : 75 - 76
  • [5] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Paul K. Winner
    Andrew M. Blumenfeld
    Eric J. Eross
    Amelia C. Orejudos
    Debbie L. Mirjah
    Aubrey Manack Adams
    Mitchell F. Brin
    Drug Safety, 2019, 42 : 1013 - 1024
  • [6] ONABOTULINUMTOXINA IS WELL TOLERATED IN CHRONIC MIGRAINE PATIENTS TAKING ORAL PREVENTIVE MEDICATIONS: LONG-TERM COMPEL ANALYSIS BY TREATMENT CYCLE
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Brin, Mitchell F.
    TOXICON, 2018, 156 : S114 - S114
  • [7] Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results From the COMPEL Study
    Blumenfeld, A. M.
    Luo, L.
    Yedigarova, L.
    Lipton, R. B.
    HEADACHE, 2020, 60 : 101 - 101
  • [8] Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study
    Blumenfeld, Andrew
    Luo, Lei
    Yedigarova, Larisa
    Lipton, Richard
    NEUROLOGY, 2020, 94 (15)
  • [9] Efficacy, tolerability, and safety of onabotulinumtoxinA treatment for chronic migraine in patients with acute medication overuse: analysis of the PREEMPT and COMPEL trials
    Agosti, R.
    Straube, A.
    Diener, H. C.
    Freeman, M.
    Pascual Gomez, J.
    Seminerio, M.
    Delahaye, L.
    Stark, R. J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [10] Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
    Blumenfeld, Andrew M.
    Stark, Richard J.
    Freeman, Marshall C.
    Orejudos, Amelia
    Adams, Aubrey Manack
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
12345